By midafternoon, shares had added 5.1% to $3.28. Since the beginning of the year, the stock has exploded 558%.
Trading volume of 19.6 million shares had exceeded its three-month daily average of 13.2 million.
From Thursday to Saturday, the radioisotope specialist will host a booth at the Annual Meeting of the American Brachytherapy Society (ABS) in San Diego.
In addition, IsoRay's Cesium-131 will feature in five separate panels where prominent specialists will discuss their experiences. Cesium-131 is a method of concentrating radiation in cancer treatment.
"Management believes that all studies will show exceptional results realized in all areas of the body where Cesium-131, or the physics associated with Cesium-131, was used," said CEO Dwight Babcock in a statement.
"With the ongoing publication of positive study results like these, the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients," he continued.